The short version of Reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Aam papad, a mango preserve from the Indian subcontinent Aiyu jelly, a jelly made from the gel from the seeds of the awkeotsang creeping fig found in Taiwan and East Asian countries. Almond jelly, a sweet dessert from Hong Kong Bocadillo, a Latin American confectionery made with guava pulp and panela Cedrate fruit, from Northern Iran, is made into a jam called morabbā-ye bālang Chakkavaratti, a Southern Indian jackfruit preserve made with jaggery. Coffee jelly features in many desserts in Japan Jellied cranberry sauce is primarily a holiday treat in the US and the UK. Götterspeise, a German dessert made of gelatine or other gelling agent Grass jelly, a food from China and Southeast Asia, often served in drinks Hitlerszalonna ('Hitler's bacon'), sold today as gyümölcs íz. The original name comes from the scarcity of real bacon during wartime. This dense fruit jam was eaten by Hungarian troops and civilians during World War II. It was made from mixed fruits such as plum and sold in brick-shaped blocks. Konjac, a variety of Japanese jelly made from konnyaku Jell-O was named the official snack food of the US state of Utah in 2001. A bowl of lime-flavoured gelatine was featured on a pin for the 2002 Winter Olympics held in Salt Lake City. Mayhaw jelly is a delicacy in parts of the American South. Muk, a variety of Korean jelly, seasoned and eaten as a cold salad Nata de coco, jelly made from coconuts originating from the Philippines Turkish delight, a jelly type of Turkish dessert Yōkan, a sweet, pasty jelly dessert from Japan often made with beans, sweet potato or squash
== Dental considerations == The protocols suggest the use of factor concentrate along with the use of local hemostatic techniques, such as suturing, and local measures, such as the use of oxidized cellulose, for example, Surgicel or fibrin glue in conjunction with post-operatively administered antifibrinolytic agents where appropriate. The use of any non-steroidal anti-inflammatory drug (NSAID) must be discussed beforehand with the patient's hematologist because of their effect on platelet aggregation. There are no restrictions regarding the type of local anaesthetic agent used although those with vasoconstrictors may provide additional local hemostasis.
Lutetium (177Lu), which decays with the emission of a low-energy electron, is useful for treating some cancerous tumors. Several compounds of 177Lu are available for this purpose: 1) Lutetium chloride, LuCl3, sold under the brand name Lumark among others, is used for radiolabeling other medicines, either as an anti-cancer therapy or for scintigraphy (medical radio-imaging). Its most common side effects are anaemia (low red blood cell counts), thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), lymphopenia (low levels of lymphocytes, a particular type of white blood cell), nausea (feeling sick), vomiting and mild and temporary hair loss. 2) Lutetium (177Lu) oxodotreotide, also known as Lutetium (177Lu) dotatate ("Lutathera"), has been approved for some types of tumors. 3) Lutetium (177Lu) vipivotide tetraxetan ("Pluvicto") has also been approved.
Sources: en.wikipedia.org
He also founded the Collective Investigation Record for the British Medical Association; this organization collected data from physicians practicing outside the hospital setting and was the precursor of modern collaborative clinical trials."
An enzyme is a biological macromolecule, usually a protein, that acts as a biological catalyst, accelerating chemical reactions without being consumed in the process. The molecules on which enzymes act are called substrates, which are converted into products. Nearly all metabolic processes within a cell depend on enzyme catalysis to occur at biologically relevant rates. A metabolic pathway is typically composed of a series of enzyme-catalyzed steps. The study of enzymes is known as enzymology, and a related field focuses on pseudoenzymes—proteins that have lost catalytic activity but may retain regulatory or scaffolding functions, often indicated by alterations in their amino acid sequences or unusual 'pseudocatalytic' behavior. Enzymes are known to catalyze over 5,000 types of biochemical reactions. Other biological catalysts include catalytic RNA molecules, or ribozymes, which are sometimes classified as enzymes despite being composed of RNA rather than protein. More recently, biomolecular condensates have been recognized as a third category of biocatalysts, capable of catalyzing reactions by creating interfaces and gradients—such as ionic gradients—that drive biochemical processes, even when their component proteins are not intrinsically catalytic. Enzymes increase the reaction rate by lowering a reaction's activation energy, often by factors of millions. A striking example is orotidine 5′-phosphate decarboxylase, which accelerates a reaction that would otherwise take millions of years to occur in milliseconds.
== Management and treatment == Peyronie's disease treatment is based on stage of disease, degree of curvature, loss of function, and patient choice. Conservative management in the acute phase has the aim of reducing inflammation and disease extension.
Sources: en.wikipedia.org
The wound-healing process is not only complex but fragile, and it is susceptible to interruption or failure leading to the formation of non-healing chronic wounds. Factors that contribute to non-healing chronic wounds are diabetes, venous or arterial disease, infection, and metabolic deficiencies of old age. Wound care encourages and speeds wound healing via cleaning and protection from reinjury or infection. Depending on each patient's needs, it can range from the simplest first aid to entire nursing specialties such as wound, ostomy, and continence nursing and burn center care.
Natural casings are produced and sold almost exclusively by the hank which is a unit of measure that is 91 meters long. A hank can consist of a varying number of strands (individual pieces of casing) which vary in length from 2 meters (which is the shortest length sold for commercial use) to as long as 28 meters. Each casing manufacturer has various "put ups" which dictate the maximum number of strands and the minimum length of each strand allowed in the put up. Casings are selected for size which is measured in millimeters and refers to the diameter of the casing; this is done exclusively by hand and is primarily done in China due to the availability of low cost labor. Commercially casings are available in various forms of packaging which are suited to different applications. Sheep/lamb and hog are available in all packaging types due to the high demand and long length of pieces; due to the shorter length and much lower demand for beef casings they are primarily only available loose or in net packs either salted or in brine.
=== Congenital cataract === In humans, a novel mutation of the COL4A1 gene coding for collagen type IV was found to be associated with autosomal dominant congenital cataract in a Chinese family. This mutation was not found in unaffected family members or in 200 unrelated controls. In this study, sequence analysis confirmed that the Gly782 amino acid residue was highly conserved. This report of a new mutation in the COL4A1 gene is the first report of a non-syndromic autosomal dominant congenital cataract that highlights an important role for collagen type IV in the physiological and optical properties of the lens.
== Samarium-149 == Samarium-149 (149Sm) is an observationally stable isotope of samarium (predicted to decay, but no decays have ever been observed, giving it a half-life at least several orders of magnitude longer than the age of the universe), and a product of the decay chain from the fission product 149Nd (yield 1.0888%). 149Sm is a neutron-absorbing nuclear poison with significant effect on nuclear reactor operation, second only to 135Xe. Its neutron cross section is 40140 barns for thermal neutrons. The equilibrium concentration (and thus the poisoning effect) builds to an equilibrium value in about 500 hours (about 20 days) of reactor operation, and since 149Sm is stable, the concentration remains essentially constant during further reactor operation. This contrasts with xenon-135, which accumulates from the beta decay of iodine-135 (a short lived fission product) and has a high neutron cross section, but itself decays with a half-life of 9.2 hours (so does not remain in constant concentration long after the reactor shutdown), causing the so-called xenon pit.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.